MedPath

A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Children Who Cannot Take Trimethoprim-Sulfamethoxazole

Phase 1
Completed
Conditions
Pneumonia, Pneumocystis Carinii
HIV Infections
Registration Number
NCT00001027
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

Primary: To compare the pharmacokinetics of biweekly and monthly dose regimens of intravenous pentamidine in HIV-infected infants and children who require PCP prophylaxis and who are intolerant to oral trimethoprim - sulfamethoxazole. To determine the safety and tolerance of these regimens in this patient population.

Secondary: To obtain information on the rate of PCP breakthrough in infants and children receiving parenteral pentamidine prophylaxis.

Prophylaxis against Pneumocystis carinii pneumonia is recommended for all HIV-infected children considered to be at high risk. In children younger than 5 years of age with intolerance to trimethoprim - sulfamethoxazole, parenteral pentamidine may be a successful alternative.

Detailed Description

Prophylaxis against Pneumocystis carinii pneumonia is recommended for all HIV-infected children considered to be at high risk. In children younger than 5 years of age with intolerance to trimethoprim - sulfamethoxazole, parenteral pentamidine may be a successful alternative.

Thirty-two children are randomized to one of two treatment arms. Patients receive pentamidine on either a biweekly or a monthly treatment schedule. Treatment continues until the last child enrolled has received at least 6 months of pentamidine. Patients are stratified according to age \< 24 months or age \>= 24 months. Steady-state pharmacokinetics will be examined in a subsample of 20 patients.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
32
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (13)

Usc La Nichd Crs

🇺🇸

Los Angeles, California, United States

Chicago Children's CRS

🇺🇸

Chicago, Illinois, United States

UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS

🇺🇸

Los Angeles, California, United States

Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS

🇵🇷

San Juan, Puerto Rico

Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease

🇺🇸

Chicago, Illinois, United States

Harlem Hosp. Ctr. NY NICHD CRS

🇺🇸

New York, New York, United States

SUNY Upstate Med. Univ., Dept. of Peds

🇺🇸

Syracuse, New York, United States

NYU Med. Ctr., Dept. of Medicine

🇺🇸

New York, New York, United States

Tulane/LSU Maternal/Child CRS

🇺🇸

New Orleans, Louisiana, United States

Children's National Med. Ctr., ACTU

🇺🇸

Washington, District of Columbia, United States

Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab.

🇺🇸

Oakland, California, United States

Howard Univ. Washington DC NICHD CRS

🇺🇸

Washington, District of Columbia, United States

San Juan City Hosp. PR NICHD CRS

🇵🇷

San Juan, Puerto Rico

© Copyright 2025. All Rights Reserved by MedPath